Bring Your Toughest AM Quality Problem To Formnext: Amsight Challenges Manufacturers To Rethink Production Quality 
Mentionkit Publishes SourcetoMCP Case Study on Social Listening for B2B SaaS Impel NeuroPharma Announces Pricing of $45.0 Million Public Offering
SEATTLE, Sept. 09, 2021 (GLOBE NEWSWIRE) — Impel NeuroPharma, Inc. (NASDAQ: IMPL), a commercial-stage biopharmaceutical…
InMed Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
VANCOUVER, British Columbia, Sept. 09, 2021 (GLOBE NEWSWIRE) — InMed Pharmaceuticals Inc. (“InMed” or the…
T2 Biosystems T2SARS-CoV-2™ Panel Proves Capable of Detecting the Mu B.1.621 and Iota B.1.526 Variants of the SARS-CoV-2 Virus
LEXINGTON, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the…
BioCardia Announces Participation at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021 (Virtual Conference)
SAN CARLOS, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) — BioCardia®, Inc. (Nasdaq: BCDA), today announced it…
atai Life Sciences and Introspect Digital Therapeutics to test novel digital therapeutic approach in patients receiving ketamine for treatment resistant depression
BERLIN and SAN DIEGO, Sept. 09, 2021 (GLOBE NEWSWIRE) — atai Life Sciences (Nasdaq: ATAI) (“atai”), a clinical-stage…
Gain Therapeutics to Present at 2021 International Virtual GM1 Community Conference
BETHESDA, Md., Sept. 09, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or…
EyeGate to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
WALTHAM, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or…
Arcutis to Present at Upcoming Investor Conferences
WESTLAKE VILLAGE, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage…
Codexis and Merck Amend and Extend Supply Agreement for Enzyme Used in Manufacture of Sitagliptin
REDWOOD CITY, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) — Codexis, Inc. (Nasdaq: CDXS), a leading…
Apellis Announces Top-Line Results from Phase 3 DERBY and OAKS Studies in Geographic Atrophy (GA) and Plans to Submit NDA to FDA in the First Half of 2022
OAKS met the primary endpoint for both monthly and every-other-month treatment with pegcetacoplan, demonstrating a…
Gritstone to Host Data Update on Neoantigen Oncology Programs for the Treatment of Solid Tumors During ESMO 2021
EMERYVILLE, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) — Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage…
Rezolute Announces Initiation of Dosing in the Second Cohort of its Phase 2b Trial of RZ358 for Congenital Hyperinsulinism
Tracking to Announce Top line data in Q1 2022 REDWOOD CITY, Calif., Sept. 09, 2021…
AnaptysBio to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
SAN DIEGO, Sept. 09, 2021 (GLOBE NEWSWIRE) — AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology…
TScan Therapeutics Appoints Zoran Zdraveski, J.D., Ph.D. as Chief Legal Officer
WALTHAM, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) — TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical…
Oncternal Therapeutics to Participate in September Investor Conferences
SAN DIEGO, Sept. 09, 2021 (GLOBE NEWSWIRE) — Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage…
Tempest to Present at Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) — Tempest Therapeutics, Inc. (Nasdaq: TPST),…
Mountain Valley MD Holdings Announces Annual Shareholder Meeting
TORONTO, Sept. 09, 2021 (GLOBE NEWSWIRE) — Mountain Valley MD Holdings Inc. (the “Company” or…
Oxurion NV Business & Financial Update – H1 2021
Developing Next generation Standard of Care Ophthalmic Therapies Addressing Unmet Medical Needs in Retinal Vascular…
Rakovina Therapeutics to Present at the JCA-AACR Precision Medicine International Conference
VANCOUVER, British Columbia, Sept. 09, 2021 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSXV: RKV) (“the…
Clarus Therapeutics Closes Transaction With Blue Water, Debuts as a Publicly Traded Company to Develop Androgen and Metabolic Therapies
Business combination with Blue Water Acquisition Corp., a special purpose acquisition company, completed on September 9, 2021 Combined company to be…